Circulating adiponectin levels are inversely associated with risk of various obesity-related cancers. However, the effect of adiponectin on carcinogenesis and progression of tongue squamous cell carcinoma (TSCC) remains unknown. We measured serum adiponectin levels in 59 patients with TSCC and 50 healthy controls. Expression of adiponectin and its receptors in paired tumor and paracancerous specimens were determined by immunohistochemical staining (n = 37) and western blot (n = 30), respectively. Serum adiponectin level was lower in patients than in controls (5.0 AE 2.4 vs 8.4 AE 3.5 lg ⁄ mL, P < 0.01), and was inversely associated with histological grade and lymph node metastasis but not tumor size. Local adiponectin levels in tumor tissue gradually decreased as tumor-node-metastasis stage increased, while the expression of adiponectin receptors was unchanged. In addition, serum adiponectin levels in the TSCC patients without metabolic and cardiovascular diseases, or without smoking and drinking habits, were still lower than in controls. Furthermore, adiponectin inhibited the migration, but not proliferation, of SCC15 cells in vitro. These results indicate that a decreased adiponectin level is associated with risk of TSCC. Hypoadiponectinemia might be used as a biomarker to predict an aggressive phenotype of TSCC. (Cancer Sci 2013; 104: 206-213) T ongue squamous cell carcinoma (TSCC) is one of the most common cancers in the oral cavity and is characterized by rapid growth, diffuse invasion, high propensity for cervical nodal metastasis and high recurrence.(1) Lymph node metastasis affects the probability of regional control and is the strongest prognostic factor for survival with TSCC.(2) Despite refinement of surgical techniques and chemotherapy or radiotherapy, 5-year survival is still unsatisfactory.(3) Considerable epidemiological evidence indicates that smoking, alcohol intake, chronic mechanical stimulation and betel quid chewing are associated with the incidence of TSCC, (4,5) but the molecular mechanisms responsible for TSCC remain unclear. Furthermore, TSCC has become increasingly prevalent among young and middle-aged populations.(5) Therefore, it is necessary to develop new strategies to improve the diagnosis and therapy for TSCC.Adiponectin is an adipokine produced predominantly by adipocytes that circulates abundantly in plasma.(6) Adiponectin acts through two different membrane-bound adiponectin receptors, AdipoR1 and AdipoR2, and functions as an anti-diabetic, anti-atherogenic, anti-inflammatory and anti-angiogenic hormone. (7,8) Circulating adiponectin levels are lower in patients with obesity, type 2 diabetes and coronary artery disease. (8,9) Hypoadiponectinemia may be a biomarker for metabolic and cardiovascular diseases. Recent epidemiological studies indicate that hypoadiponectinemia is associated with risk of various cancers, including breast, endometrial, and colorectal cancers.(10-12) In addition, adiponectin has anti-proliferative and pro-apoptotic effects on breast cancer cells.(13) ...